Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$136.3 million.

  • Cullinan Therapeutics' Cash from Investing Activities rose 279.90% to $51.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $35.8 million, marking a year-over-year decrease of 85.62%. This contributed to the annual value of -$136.3 million for FY2024, which is 480.70% down from last year.
  • Cullinan Therapeutics' Cash from Investing Activities amounted to -$136.3 million in FY2024, which was down 480.70% from $35.8 million recorded in FY2023.
  • Cullinan Therapeutics' 5-year Cash from Investing Activities high stood at $249.0 million for FY2022, and its period low was -$333.8 million during FY2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $35.8 million (2023), whereas its average is $49.5 million.
  • As far as peak fluctuations go, Cullinan Therapeutics' Cash from Investing Activities plummeted by 6,058.21% in 2021, and later spiked by 174.59% in 2022.
  • Yearly analysis of 5 years shows Cullinan Therapeutics' Cash from Investing Activities stood at -$5.4 million in 2020, then tumbled by 6,058.21% to -$333.8 million in 2021, then soared by 174.59% to $249.0 million in 2022, then crashed by 85.62% to $35.8 million in 2023, then slumped by 480.70% to -$136.3 million in 2024.